“The oral diabetes drug metformin could potentially play a role as an adjuvant treatment in the management of endometrial cancer, according to results from an in vitro study carried out in England…”
The fact is that there are many evidence-based, non-conventional therapies (such as metformin) shown to manage endometrial cancer. These therapies are not in oncologists offices because board certified oncologists can only, by law, prescribe therapies approved by the Food and Drug Administration (FDA).
If you have been diagnosed with endometrial cancer you may want to understand the full spectrum of therapies that are available to you. Certainly surgery to excise any cancer inside you is your first step. Depending on your stage at diagnosis you may want to add chemotherapy to your regimen. And perhaps evidence-based therapies too.
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
“Metformin (BP, pronounced met-fawr-min; originally sold as Glucophage) is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes, in particular, in overweight and obese people and those with normal kidney function. Its use in gestational diabetes has been limited by safety concerns. It is also used in the treatment of polycystic ovary syndrome, and has been investigated for other diseases where insulin resistance may be an important factor. Metformin works by suppressing glucose production by the liver.
“The oral diabetes drug metformin could potentially play a role as an adjuvant treatment in the management of endometrial cancer, according to results from an in vitro study carried out in England…
“Insulin sensitizers, in particular, the biguanide metformin, are widely used in the management of women with polycystic ovary syndrome (PCOS). Metformin not only ameliorates insulin resistance and hyperinsulinemia in PCOS women, but also its long-term use improves ovulation and menstrual cycle regularity,” the authors write.
In addition to suppressing glucose production in the liver, metformin has demonstrated beneficial effects in other types of tissues, including adipose tissue, skeletal muscle, and the vascular endothelium. More recently, the drug has also been shown to inhibit the growth of breast cancer cells.
Because women with insulin-resistant states are more likely to develop endometrial cancer, the researchers decided to use various assays to study the invasive qualities of lab-obtained human endometrial cancer cells (ECC-1) in sera samples obtained from a cohort of 21 women both before and after they had undergone a 6-month course of metformin (850 mg twice daily). Those results were compared with those of a group of matched control participants…”